An explainable foundation model for drug repurposing

Alaa Bessadok,Francesca Grisoni

DOI: https://doi.org/10.1038/s41591-024-03333-8

IF: 82.9

2024-10-25

Nature Medicine

Abstract:A foundation model leverages large-scale medical knowledge to repurpose drugs for diseases that currently lack approved treatments, and provides explanations to support clinicians' decisions.

biochemistry & molecular biology,cell biology,medicine, research & experimental

What problem does this paper attempt to address?

A foundation model for clinician-centered drug repurposing

Kexin Huang,Payal Chandak,Qianwen Wang,Shreyas Havaldar,Akhil Vaid,Jure Leskovec,Girish N. Nadkarni,Benjamin S. Glicksberg,Nils Gehlenborg,Marinka Zitnik

DOI: https://doi.org/10.1038/s41591-024-03233-x

IF: 82.9

2024-09-26

Nature Medicine

Abstract:Drug repurposing—identifying new therapeutic uses for approved drugs—is often a serendipitous and opportunistic endeavour to expand the use of drugs for new diseases. The clinical utility of drug-repurposing artificial intelligence (AI) models remains limited because these models focus narrowly on diseases for which some drugs already exist. Here we introduce TxGNN, a graph foundation model for zero-shot drug repurposing, identifying therapeutic candidates even for diseases with limited treatment options or no existing drugs. Trained on a medical knowledge graph, TxGNN uses a graph neural network and metric learning module to rank drugs as potential indications and contraindications for 17,080 diseases. When benchmarked against 8 methods, TxGNN improves prediction accuracy for indications by 49.2% and contraindications by 35.1% under stringent zero-shot evaluation. To facilitate model interpretation, TxGNN's Explainer module offers transparent insights into multi-hop medical knowledge paths that form TxGNN's predictive rationales. Human evaluation of TxGNN's Explainer showed that TxGNN's predictions and explanations perform encouragingly on multiple axes of performance beyond accuracy. Many of TxGNN's new predictions align well with off-label prescriptions that clinicians previously made in a large healthcare system. TxGNN's drug-repurposing predictions are accurate, consistent with off-label drug use, and can be investigated by human experts through multi-hop interpretable rationales.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Explainable drug repurposing via path based knowledge graph completion

Ana Jiménez,María José Merino,Juan Parras,Santiago Zazo

DOI: https://doi.org/10.1038/s41598-024-67163-x

IF: 4.6

2024-07-20

Scientific Reports

Abstract:Drug repurposing aims to find new therapeutic applications for existing drugs in the pharmaceutical market, leading to significant savings in time and cost. The use of artificial intelligence and knowledge graphs to propose repurposing candidates facilitates the process, as large amounts of data can be processed. However, it is important to pay attention to the explainability needed to validate the predictions. We propose a general architecture to understand several explainable methods for graph completion based on knowledge graphs and design our own architecture for drug repurposing. We present XG4Repo (eXplainable Graphs for Repurposing), a framework that takes advantage of the connectivity of any biomedical knowledge graph to link compounds to the diseases they can treat. Our method allows methapaths of different types and lengths, which are automatically generated and optimised based on data. XG4Repo focuses on providing meaningful explanations to the predictions, which are based on paths from compounds to diseases. These paths include nodes such as genes, pathways, side effects, or anatomies, so they provide information about the targets and other characteristics of the biomedical mechanism that link compounds and diseases. Paths make predictions interpretable for experts who can validate them and use them in further research on drug repurposing. We also describe three use cases where we analyse new uses for Epirubicin, Paclitaxel, and Predinisone and present the paths that support the predictions.

multidisciplinary sciences
Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network

Jiannan Yang,Zhen Li,William Ka Kei Wu,Shi Yu,Zhongzhi Xu,Qian Chu,Qingpeng Zhang

DOI: https://doi.org/10.1093/bib/bbac469

IF: 9.5

2022-11-09

Briefings in Bioinformatics

Abstract:The discovery and repurposing of drugs require a deep understanding of the mechanism of drug action (MODA). Existing computational methods mainly model MODA with the protein–protein interaction (PPI) network. However, the molecular interactions of drugs in the human body are far beyond PPIs. Additionally, the lack of interpretability of these models hinders their practicability. We propose an interpretable deep learning-based path-reasoning framework (iDPath) for drug discovery and repurposing by capturing MODA on by far the most comprehensive multilayer biological network consisting of the complex high-dimensional molecular interactions between genes, proteins and chemicals. Experiments show that iDPath outperforms state-of-the-art machine learning methods on a general drug repurposing task. Further investigations demonstrate that iDPath can identify explicit critical paths that are consistent with clinical evidence. To demonstrate the practical value of iDPath, we apply it to the identification of potential drugs for treating prostate cancer and hypertension. Results show that iDPath can discover new FDA-approved drugs. This research provides a novel interpretable artificial intelligence perspective on drug discovery.

biochemical research methods,mathematical & computational biology
DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning

Yoshitaka Inoue,Tianci Song,Tianfan Fu

2024-09-17

Abstract:Drug repurposing offers a promising avenue for accelerating drug development by identifying new therapeutic potentials of existing drugs. In this paper, we propose a multi-agent framework to enhance the drug repurposing process using state-of-the-art machine learning techniques and knowledge integration. Our framework comprises several specialized agents: an AI Agent trains robust drug-target interaction (DTI) models; a Knowledge Graph Agent utilizes the drug-gene interaction database (DGIdb), DrugBank, Comparative Toxicogenomics Database (CTD), and Search Tool for Interactions of Chemicals (STITCH) to systematically extract DTIs; and a Search Agent interacts with biomedical literature to annotate and verify computational predictions. By integrating outputs from these agents, our system effectively harnesses diverse data sources, including external databases, to propose viable repurposing candidates. Preliminary results demonstrate the potential of our approach in not only predicting drug-disease interactions but also in reducing the time and cost associated with traditional drug discovery methods. This paper highlights the scalability of multi-agent systems in biomedical research and their role in driving innovation in drug repurposing. Our approach not only outperforms existing methods in predicting drug repurposing potential but also provides interpretable results, paving the way for more efficient and cost-effective drug discovery processes.

Artificial Intelligence,Computation and Language,Information Retrieval,Machine Learning,Quantitative Methods
Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Anup P Challa,Nicole M Zaleski,Rebecca N Jerome,Robert R Lavieri,Jana K Shirey-Rice,April Barnado,Christopher J Lindsell,David M Aronoff,Leslie J Crofford,Raymond C Harris,T Alp Ikizler,Ingrid A Mayer,Kenneth J Holroyd,Jill M Pulley

DOI: https://doi.org/10.3389/fgene.2021.707836

2021-07-28

Abstract:Repurposing is an increasingly attractive method within the field of drug development for its efficiency at identifying new therapeutic opportunities among approved drugs at greatly reduced cost and time of more traditional methods. Repurposing has generated significant interest in the realm of rare disease treatment as an innovative strategy for finding ways to manage these complex conditions. The selection of which agents should be tested in which conditions is currently informed by both human and machine discovery, yet the appropriate balance between these approaches, including the role of artificial intelligence (AI), remains a significant topic of discussion in drug discovery for rare diseases and other conditions. Our drug repurposing team at Vanderbilt University Medical Center synergizes machine learning techniques like phenome-wide association study-a powerful regression method for generating hypotheses about new indications for an approved drug-with the knowledge and creativity of scientific, legal, and clinical domain experts. While our computational approaches generate drug repurposing hits with a high probability of success in a clinical trial, human knowledge remains essential for the hypothesis creation, interpretation, "go-no go" decisions with which machines continue to struggle. Here, we reflect on our experience synergizing AI and human knowledge toward realizable patient outcomes, providing case studies from our portfolio that inform how we balance human knowledge and machine intelligence for drug repurposing in rare disease.
DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

Yinyin Wang,Jehad Aldahdooh,Yingying Hu,Hongbin Yang,Markus Vähä-Koskela,Jing Tang,Ziaurrehman Tanoli

DOI: https://doi.org/10.1038/s41598-022-24980-2

IF: 4.6

2022-12-08

Scientific Reports

Abstract:The drug development process consumes 9–12 years and approximately one billion US dollars in costs. Due to the high finances and time costs required by the traditional drug discovery paradigm, repurposing old drugs to treat cancer and rare diseases is becoming popular. Computational approaches are mainly data-driven and involve a systematic analysis of different data types leading to the formulation of repurposing hypotheses. This study presents a novel scoring algorithm based on chemical and genomic data to repurpose drugs for 669 diseases from 22 groups, including various cancers, musculoskeletal, infections, cardiovascular, and skin diseases. The data types used to design the scoring algorithm are chemical structures, drug-target interactions (DTI), pathways, and disease-gene associations. The repurposed scoring algorithm is strengthened by integrating the most comprehensive manually curated datasets for each data type. At DrugRepo score ≥ 0.4, we repurposed 516 approved drugs across 545 diseases. Moreover, hundreds of novel predicted compounds can be matched with ongoing studies at clinical trials. Our analysis is supported by a web tool available at: http://drugrepo.org/.

multidisciplinary sciences
Knowledge-driven drug repurposing using a comprehensive drug knowledge graph

Yongjun Zhu,Chao Che,Bo Jin,Ningrui Zhang,Chang Su,Fei Wang

DOI: https://doi.org/10.1177/1460458220937101

Abstract:Due to the huge costs associated with new drug discovery and development, drug repurposing has become an important complement to the traditional de novo approach. With the increasing number of public databases and the rapid development of analytical methodologies, computational approaches have gained great momentum in the field of drug repurposing. In this study, we introduce an approach to knowledge-driven drug repurposing based on a comprehensive drug knowledge graph. We design and develop a drug knowledge graph by systematically integrating multiple drug knowledge bases. We describe path- and embedding-based data representation methods of transforming information in the drug knowledge graph into valuable inputs to allow machine learning models to predict drug repurposing candidates. The evaluation demonstrates that the knowledge-driven approach can produce high predictive results for known diabetes mellitus treatments by only using treatment information on other diseases. In addition, this approach supports exploratory investigation through the review of meta paths that connect drugs with diseases. This knowledge-driven approach is an effective drug repurposing strategy supporting large-scale prediction and the investigation of case studies.
Knowledge Graphs and Explainable AI for Drug Repurposing on Rare Diseases

Pablo Perdomo-Quinteiro,Katy Wolstencroft,Marco Roos,Nuria Queralt-Rosinach

DOI: https://doi.org/10.1101/2024.10.17.618804

2024-10-17

Abstract:Artificial Intelligence (AI)-based drug repurposing is an emerging strategy to identify drug candidates to treat rare diseases. However, cutting-edge algorithms based on Deep Learning (DL) typically dont provide a human understandable explanation supporting their predictions. This is a problem because it hampers the biologists ability to decide which predictions are the most plausible drug candidates to test in costly lab experiments. In this study, we propose rd-explainer a novel AI drug repurposing method for rare diseases which obtains possible drug candidates together with human understandable explanations. The method is based on Graph Neural Network (GNN) technology and explanations were generated as semantic graphs using state-of-the-art eXplainable AI (XAI). The model learns features from current background knowledge on the target rare disease structured as a Knowledge Graph (KG), which integrates curated facts and their evidence on different biomedical entities such as symptoms, drugs, genes and ortholog genes. Our experiments demonstrate that our method has excellent performance that is superior to state-of the-art models. We investigated the application of XAI on drug repurposing for rare diseases and we prove our method is capable of discovering plausible drug candidates based on testable explanations. The data and code are publicly available at https://github.com/PPerdomoQ/rare-disease-explainer.

Bioinformatics
Repurposing – second life for drugs

Porkodi Ayyar,Umamaheswari Subramanian

DOI: https://doi.org/10.3897/pharmacia.69.e72548

2022-01-05

Pharmacia

Abstract:Drug repurposing refers to finding new indications for existing drugs. The paradigm shift from traditional drug discovery to drug repurposing is driven by the fact that new drug pipelines are getting dried up because of mounting Research & Development (R&D) costs, long timeline for new drug development, low success rate for new molecular entities, regulatory hurdles coupled with revenue loss from patent expiry and competition from generics. Anaemic drug pipelines along with increasing demand for newer effective, cheaper, safer drugs and unmet medical needs call for new strategies of drug discovery and, drug repurposing seems to be a promising avenue for such endeavours. Drug repurposing strategies have progressed over years from simple serendipitous observations to more complex computational methods in parallel with our ever-growing knowledge on drugs, diseases, protein targets and signalling pathways but still the knowledge is far from complete. Repurposed drugs too have to face many obstacles, although lesser than new drugs, before being successful.
DrugReAlign: a multisource prompt framework for drug repurposing based on large language models

Jinhang Wei,Linlin Zhuo,Xiangzheng Fu,XiangXiang Zeng,Li Wang,Quan Zou,Dongsheng Cao

DOI: https://doi.org/10.1186/s12915-024-02028-3

IF: 7.364

2024-10-11

BMC Biology

Abstract:Drug repurposing is a promising approach in the field of drug discovery owing to its efficiency and cost-effectiveness. Most current drug repurposing models rely on specific datasets for training, which limits their predictive accuracy and scope. The number of both market-approved and experimental drugs is vast, forming an extensive molecular space. Due to limitations in parameter size and data volume, traditional drug-target interaction (DTI) prediction models struggle to generalize well within such a broad space. In contrast, large language models (LLMs), with their vast parameter sizes and extensive training data, demonstrate certain advantages in drug repurposing tasks. In our research, we introduce a novel drug repurposing framework, DrugReAlign, based on LLMs and multi-source prompt techniques, designed to fully exploit the potential of existing drugs efficiently. Leveraging LLMs, the DrugReAlign framework acquires general knowledge about targets and drugs from extensive human knowledge bases, overcoming the data availability limitations of traditional approaches. Furthermore, we collected target summaries and target-drug space interaction data from databases as multi-source prompts, substantially improving LLM performance in drug repurposing. We validated the efficiency and reliability of the proposed framework through molecular docking and DTI datasets. Significantly, our findings suggest a direct correlation between the accuracy of LLMs' target analysis and the quality of prediction outcomes. These findings signify that the proposed framework holds the promise of inaugurating a new paradigm in drug repurposing.

biology
Recent advances in drug repurposing using machine learning

Fabio Urbina,Ana C Puhl,Sean Ekins

DOI: https://doi.org/10.1016/j.cbpa.2021.06.001

Abstract:Drug repurposing aims to find new uses for already existing and approved drugs. We now provide a brief overview of recent developments in drug repurposing using machine learning alongside other computational approaches for comparison. We also highlight several applications for cancer using kinase inhibitors, Alzheimer's disease as well as COVID-19.
SynDRep: A Knowledge Graph-Enhanced Tool based on Synergistic Partner Prediction for Drug Repurposing

Karim S. Shalaby,Sathvik Guru Rao,Bruce Schultz,Martin Hofmann-Apitius,Alpha Tom Kodamullil,Vinay Srinivas Bharadhwaj

DOI: https://doi.org/10.1101/2024.08.13.607713

2024-10-11

Abstract:Motivation: Drug repurposing is gaining interest due to its high cost-effectiveness, low risks, and improved patient outcomes. However, most drug repurposing methods depend on drug-disease-target semantic connections of a single drug rather than insights from drug combination data. In this study, we propose SynDRep, a novel drug repurposing tool based on enriching knowledge graphs (KG) with drug combination effects. It predicts the synergistic drug partner with a commonly prescribed drug for the target disease, leveraging graph embedding and machine learning techniques. This partner drug is then repurposed as a single agent for this disease by exploring pathways between them in KG. Results: HolE was the best-performing embedding model (with 84.58% of true predictions for all relations), and random forest emerged as the best ML model with an ROC-AUC value of 0.796. Some of our selected candidates, such as miconazole and albendazole for Alzheimer's disease, have been validated through literature, while others lack either a clear pathway or literature evidence for their use for the disease of interest. Therefore, complementing SynDRep with more specialized KG, and additional training data, would enhance its efficacy and offer cost-effective and timely solutions for patients. Availability and Implementation: SynDRep is available as an open-source Python package at https://github.com/SynDRep/SynDRep under the Apache 2.0 License.

Bioinformatics
Drug repurposing: progress, challenges and recommendations

Sudeep Pushpakom,Francesco Iorio,Patrick A. Eyers,K. Jane Escott,Shirley Hopper,Andrew Wells,Andrew Doig,Tim Guilliams,Joanna Latimer,Christine McNamee,Alan Norris,Philippe Sanseau,David Cavalla,Munir Pirmohamed,Sudeep Pushpakom,Francesco Iorio,Patrick A. Eyers,K. Jane Escott,Shirley Hopper,Andrew Wells,Andrew Doig,Tim Guilliams,Joanna Latimer,Christine McNamee,Alan Norris,Philippe Sanseau,David Cavalla,Munir Pirmohamed

DOI: https://doi.org/10.1038/nrd.2018.168

IF: 112.288

2018-10-12

Nature Reviews Drug Discovery

Abstract:Drug repurposing — a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication — has the potential for greater success rates and reduced costs compared with developing entirely new drugs. Pirmohamed and colleagues present approaches used for drug repurposing, discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed.

pharmacology & pharmacy,biotechnology & applied microbiology
Graph theory enables drug repurposing. How a mathematical model can drive the discovery of hidden Mechanisms of Action

Ruggero Gramatica,T. Di Matteo,Stefano Giorgetti,Massimo Barbiani,Dorian Bevec,Tomaso Aste

DOI: https://doi.org/10.1371/journal.pone.0084912

2013-06-05

Abstract:We introduced a methodology to efficiently exploit natural-language expressed biomedical knowledge for repurposing existing drugs towards diseases for which they were not initially intended. Leveraging on developments in Computational Linguistics and Graph Theory, a methodology is defined to build a graph representation of knowledge, which is automatically analysed to discover hidden relations between any drug and any disease: these relations are specific paths among the biomedical entities of the graph, representing possible Modes of Action for any given pharmacological compound. These paths are ranked according to their relevance, exploiting a measure induced by a stochastic process defined on the graph. Here we show, providing real-world examples, how the method successfully retrieves known pathophysiological Mode of Actions and finds new ones by meaningfully selecting and aggregating contributions from known bio-molecular interactions. Applications of this methodology are presented, and prove the efficacy of the method for selecting drugs as treatment options for rare diseases.

Quantitative Methods,Computational Engineering, Finance, and Science
A Method to Capitalise on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing

Kyriaki Savva,Margarita Zachariou,Marilena M. Bourdakou,Nikolas Dietis,George M. Spyrou

DOI: https://doi.org/10.3390/ijms25105319

IF: 5.6

2024-05-14

International Journal of Molecular Sciences

Abstract:In the area of drug research, several computational drug repurposing studies have highlighted candidate repurposed drugs, as well as clinical trial studies that have tested/are testing drugs in different phases. To the best of our knowledge, the aggregation of the proposed lists of drugs by previous studies has not been extensively exploited towards generating a dynamic reference matrix with enhanced resolution. To fill this knowledge gap, we performed weight-modulated majority voting of the modes of action, initial indications and targeted pathways of the drugs in a well-known repository, namely the Drug Repurposing Hub. Our method, DReAmocracy, exploits this pile of information and creates frequency tables and, finally, a disease suitability score for each drug from the selected library. As a testbed, we applied this method to a group of neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's disease and Multiple Sclerosis). A super-reference table with drug suitability scores has been created for all four neurodegenerative diseases and can be queried for any drug candidate against them. Top-scored drugs for Alzheimer's Disease include agomelatine, mirtazapine and vortioxetine; for Parkinson's Disease, they include apomorphine, pramipexole and lisuride; for Huntington's, they include chlorpromazine, fluphenazine and perphenazine; and for Multiple Sclerosis, they include zonisamide, disopyramide and priralfimide. Overall, DReAmocracy is a methodology that focuses on leveraging the existing drug-related experimental and/or computational knowledge rather than a predictive model for drug repurposing, offering a quantified aggregation of existing drug discovery results to (1) reveal trends in selected tracks of drug discovery research with increased resolution that includes modes of action, targeted pathways and initial indications for the investigated drugs and (2) score new candidate drugs for repurposing against a selected disease.

biochemistry & molecular biology,chemistry, multidisciplinary
System biology approaches for drug repurposing

Juveriya Israr,Shabroz Alam,Ajay kumar

DOI: https://doi.org/10.1016/bs.pmbts.2024.03.027

2024-04-06

Progress in Molecular Biology and Translational Science

Abstract:Drug repurposing, or drug repositioning, refers to the identification of alternative therapeutic applications for established medications that go beyond their initial indications. This strategy has becoming increasingly popular since it has the potential to significantly reduce the overall costs of drug development by around $300 million. System biology methodologies have been employed to facilitate medication repurposing, encompassing computational techniques such as signature matching and network-based strategies. These techniques utilize pre-existing drug-related data types and databases to find prospective repurposed medications that have minimal or acceptable harmful effects on patients. The primary benefit of medication repurposing in comparison to drug development lies in the fact that approved pharmaceuticals have already undergone multiple phases of clinical studies, thereby possessing well-established safety and pharmacokinetic properties. Utilizing system biology methodologies in medication repurposing offers the capacity to expedite the discovery of viable candidates for drug repurposing and offer novel perspectives for structure-based drug design.

biochemistry & molecular biology
KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description

Chunyu Ma,Zhihan Zhou,Han Liu,David Koslicki

DOI: https://doi.org/10.48550/arXiv.2212.01384

2023-04-25

Abstract:Background: Computational drug repurposing is a cost- and time-efficient approach that aims to identify new therapeutic targets or diseases (indications) of existing drugs/compounds. It is especially critical for emerging and/or orphan diseases due to its cheaper investment and shorter research cycle compared with traditional wet-lab drug discovery approaches. However, the underlying mechanisms of action (MOAs) between repurposed drugs and their target diseases remain largely unknown, which is still a main obstacle for computational drug repurposing methods to be widely adopted in clinical settings. Results: In this work, we propose KGML-xDTD: a Knowledge Graph-based Machine Learning framework for explainably predicting Drugs Treating Diseases. It is a two-module framework that not only predicts the treatment probabilities between drugs/compounds and diseases but also biologically explains them via knowledge graph (KG) path-based, testable mechanisms of action (MOAs). We leverage knowledge-and-publication based information to extract biologically meaningful "demonstration paths" as the intermediate guidance in the Graph-based Reinforcement Learning (GRL) path-finding process. Comprehensive experiments and case study analyses show that the proposed framework can achieve state-of-the-art performance in both predictions of drug repurposing and recapitulation of human-curated drug MOA paths. Conclusions: KGML-xDTD is the first model framework that can offer KG-path explanations for drug repurposing predictions by leveraging the combination of prediction outcomes and existing biological knowledge and publications. We believe it can effectively reduce "black-box" concerns and increase prediction confidence for drug repurposing based on predicted path-based explanations, and further accelerate the process of drug discovery for emerging diseases.

Quantitative Methods,Machine Learning
Drug Repurposing: Far Beyond New Targets for Old Drugs

T. I. Oprea,J. Mestres

DOI: https://doi.org/10.1208/s12248-012-9390-1

2012-07-24

The AAPS Journal

Abstract:Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while derisking clinical activities. This approach is of interest primarily because we continue to face significant gaps in the drug–target interactions matrix and to accumulate safety and efficacy data during clinical studies. Collecting and making publicly available as much data as possible on the target profile of drugs offer opportunities for drug repurposing, but may limit the commercial applications by patent applications. Certain clinical applications may be more feasible for repurposing than others because of marked differences in side effect tolerance. Other factors that ought to be considered when assessing drug repurposing opportunities include relevance to the disease in question and the intellectual property landscape. These activities go far beyond the identification of new targets for old drugs.
KGML-xDTD: a knowledge graph–based machine learning framework for drug treatment prediction and mechanism description

Chunyu Ma,Zhihan Zhou,Han Liu,David Koslicki

DOI: https://doi.org/10.1093/gigascience/giad057

IF: 7.658

2023-08-22

GigaScience

Abstract:Background Computational drug repurposing is a cost- and time-efficient approach that aims to identify new therapeutic targets or diseases (indications) of existing drugs/compounds. It is especially critical for emerging and/or orphan diseases due to its cheaper investment and shorter research cycle compared with traditional wet-lab drug discovery approaches. However, the underlying mechanisms of action (MOAs) between repurposed drugs and their target diseases remain largely unknown, which is still a main obstacle for computational drug repurposing methods to be widely adopted in clinical settings. Results In this work, we propose KGML-xDTD: a Knowledge Graph–based Machine Learning framework for explainably predicting Drugs Treating Diseases. It is a 2-module framework that not only predicts the treatment probabilities between drugs/compounds and diseases but also biologically explains them via knowledge graph (KG) path-based, testable MOAs. We leverage knowledge-and-publication–based information to extract biologically meaningful "demonstration paths" as the intermediate guidance in the Graph-based Reinforcement Learning (GRL) path-finding process. Comprehensive experiments and case study analyses show that the proposed framework can achieve state-of-the-art performance in both predictions of drug repurposing and recapitulation of human-curated drug MOA paths. Conclusions KGML-xDTD is the first model framework that can offer KG path explanations for drug repurposing predictions by leveraging the combination of prediction outcomes and existing biological knowledge and publications. We believe it can effectively reduce "black-box" concerns and increase prediction confidence for drug repurposing based on predicted path-based explanations and further accelerate the process of drug discovery for emerging diseases.

multidisciplinary sciences

An explainable foundation model for drug repurposing

A foundation model for clinician-centered drug repurposing

Explainable drug repurposing via path based knowledge graph completion

Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network

DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

Knowledge-driven drug repurposing using a comprehensive drug knowledge graph

Knowledge Graphs and Explainable AI for Drug Repurposing on Rare Diseases

﻿Repurposing – second life for drugs

DrugReAlign: a multisource prompt framework for drug repurposing based on large language models

Recent advances in drug repurposing using machine learning

SynDRep: A Knowledge Graph-Enhanced Tool based on Synergistic Partner Prediction for Drug Repurposing

Drug repurposing: progress, challenges and recommendations

Graph theory enables drug repurposing. How a mathematical model can drive the discovery of hidden Mechanisms of Action

A Method to Capitalise on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing

System biology approaches for drug repurposing

KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description

Drug Repurposing: Far Beyond New Targets for Old Drugs

KGML-xDTD: a knowledge graph–based machine learning framework for drug treatment prediction and mechanism description

Repurposing – second life for drugs